Delving into the Latest Updates on Mupirocin Calcium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

MUP, mupirocin, Mupirocin calcium (USP)

+ [7]

Target

IleRS

Mechanism

IleRS inhibitors(Isoleucyl-tRNA synthetase inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

MRSA - Methicillin resistant Staphylococcus aureus infectionStaphylococcal Infections

Inactive Indication

ImpetigoStreptococcal Infections

Originator Organization

GSK Plc

Active Organization

GSK PlcGlaxoSmithKline KK

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

AU (14 Aug 1991),

Staphylococcal Infections

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC52H92CaO20

InChIKeyZMGDRGVOFFKXKJ-YJGQQKNPSA-N

CAS Registry115074-43-6

The objective of this trial is 1) to evaluate the safety and clinical acceptability of a 5-day course of mupirocin applied every 8 hours (± 2 hours) to the nares, umbilical and perianal areas of infants residing in the ICU. 2) to examine the efficacy of mupirocin in eradicating SA colonization of infants in the ICU, defined as the absence of SA in cultures of the nares, umbilical, and perianal areas on day 8 (± 2) (primary decolonization) 3) to examine the efficacy of mupirocin in achieving persistent eradication of SA colonization among infants residing in the ICU,defined as the absence of SA in cultures of the nares, umbilical, and perianal areas. Duration is 36 months. Enrolled infants will continue to receive medical care as they otherwise would if they were not enrolled in the trial. The study will be powered with a primary endpoint with 126 participants. Enrollment may continue to 500 participants to power secondary and exploratory endpoints and assist design subsequent studies.

Start Date30 Apr 2014

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with Mupirocin Calcium

Login to view more data

100 Translational Medicine associated with Mupirocin Calcium

Login to view more data

100 Patents (Medical) associated with Mupirocin Calcium

Login to view more data

2,012

Literatures (Medical) associated with Mupirocin Calcium

01 Feb 2025·JOURNAL OF CHROMATOGRAPHY A

Novel strategy for multi-critical quality attributes analysis of pharmaceutical excipient polyethylene glycol by UHPLC-Q-TOF/MS

Article

Author: Liu, Qi ; Wang, Zhe ; Sun, Yutong ; Zhang, Jinlan

Polyethylene glycol (PEG) is one kind of polymeric pharmaceutical excipient widely used in pharmaceutics. The critical quality attributes (CQAs) are essential to their physicochemical properties and functions. However, there is no effective strategy to rapidly and simply analyze PEG multi-CQAs. Herein, a novel strategy was developed to simultaneously evaluate four PEG CQAs including average degree of polymerization, average molecular weight, weight-average molecular weight and polydispersity based on comprehensive identification and mathematical models of PEG components. In this strategy, an ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF/MS) method was established and different types and concentrations of mobile phase additives were optimized to overcome the mass discrimination effect of PEG components. MS data was deconvoluted by molecular feature extraction to identify PEG components with multi-charged quasimolecular ions. A total of 168 PEG components were identified in PEG mixture samples. Mathematical models were established based on the logarithmic relation between the degree of polymerization and retention time and a theoretical database including 220 detected and predicted PEG components was constructed to rapidly recognize and identify PEG components in PEG excipients and preparations samples. The calculation formulae for multi-CQAs using UHPLC-Q-TOF/MS analysis results were created, then the strategy workflow to evaluate multi-CQAs was established and validated by PEG standards, showing high efficiency for quality control of PEG excipients and their preparations.

01 Jan 2025·DRUG AND ALCOHOL REVIEW

The impact of Scotland's minimum unit pricing for alcohol policy on people accessing services for alcohol dependence: A difference‐in‐difference structured interview study

Article

Author: Boyd, Jennifer ; Little, Simon ; Johnston, Allan ; McLean, Alex ; Perkins, Andy ; Perman‐Howe, Parvati ; McCarthy, Trevor ; Hughes, Jane ; Buykx, Penny ; Holmes, John ; Livingston, Wulf ; Wright, Alex

Abstract:

Introduction:

A minimum unit price (MUP) for alcohol of £0.50 per unit (1 UK unit = 10 mL/8 g alcohol) was introduced in Scotland in May 2018. Few previous studies have examined the impact of alcohol pricing policies on people who are alcohol dependent. This study aimed to evaluate the effect of MUP on people who are alcohol dependent including changes in alcohol consumption and health status, as well as potential unintended consequences.

Methods:

Three waves of cross‐sectional data were collected in Scotland (intervention) and Northern England (control) at 0–6 months pre‐implementation then 3–9 months and 18–22 months post‐implementation. The sample was N = 706 people receiving treatment related to their alcohol use. We collected structured interview data including recent drinking information via a 7‐day timeline‐follow‐back drinking diary. Difference‐in‐difference analyses estimated change in indicators in Scotland compared to England at both post‐implementation timepoints.

Results:

The proportion of participants consuming alcohol costing on average <£0.50 per unit in Scotland decreased from 60.6% at 0–6 months prior to MUP implementation to 6.3% at 3–9 months post‐implementation (p < 0.0004). There was no significant change in the indicators for alcohol consumption, severity of dependence, health status, other substance use, deprivation level or parenting.

Discussion and Conclusions:

The introduction of MUP in Scotland was associated with increases in the prices paid for alcohol by people with dependence and presenting to treatment services. There was no evidence of changes in their alcohol consumption or health status. There was also no evidence of harmful unintended consequences for this population.

01 Jan 2025·JOURNAL OF HAZARDOUS MATERIALS

Bioaerosol emission characteristics and potential risks during composting: Focus on pathogens and antimicrobial resistance

Article

Author: Tang, Ruolan ; Ma, Ruonan ; Wang, Jiani ; Chang, Jiali ; Yuan, Jing ; Yang, Yan ; Li, Guoxue ; Jiang, Tao ; Peng, Lijuan

In this study, we analyzed bioaerosol emission characteristics and potential risks of antimicrobial resistance (AMR) during composting using the impaction culture method and metagenomic sequencing. The results showed that the highly saturated water vapor in the emission gas mitigated particulate matter emission during the thermophilic period. About the bioaerosols, the airborne aerobic bacterial emissions were suppressed as composting enters the mature period, and the airborne fungi are usually present as single-cell or small-cell aggregates (< 3.3 µm). In addition, the microbial community structure in bioaerosols was stable and independent of composting time. Most importantly, the PM_2.5 in bioaerosols contained large amounts of antibiotic resistance genes (ARGs), potential pathogens, and multidrug resistant pathogens, which were diverse and present in high concentrations. Among them, ARGs concentrations encoding 21 antibiotics ranged from - 4.50 to 0.70 ppm/m³ (Log₁₀ ARGs). Among the 89 potential human pathogens detected, Escherichia coli, Salmonella enterica, Klebsiella pneumoniae, and Staphylococcus aureus were the only culturable potentially multidrug resistant pathogens carrying multiple ARGs encoding resistance at high concentrations (- 0.57 to 1.15 ppm/m³ (Log₁₀ ARGs)), and were more likely to persist and multiply in oligotrophic environments. Our findings indicate that composting technology can transfer AMR from solid compost to gas phase and increase the risk of AMR transmission.

100 Deals associated with Mupirocin Calcium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02195	-	R01AX06 D06AX09	DB00410

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	US	GSK Plc	11 Dec 1997
Impetigo	US	GSK Plc	18 Sep 1995
MRSA - Methicillin resistant Staphylococcus aureus infection	US	GSK Plc	18 Sep 1995
Staphylococcus Aureus Infections	US	GSK Plc	18 Sep 1995
Streptococcal Infections	US	GSK Plc	18 Sep 1995
Staphylococcal Infections	AU	GSK Plc	14 Aug 1991

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04155203 (CTgov)	Phase 3	Wounds and Injuries \| Infectious Diseases	657	Mupirocin Calcium (Perrigo Active)	bntqnltfva(pvyyutnyuz) = nitfnceczv pvnzlswdap (kxeevbvfst, dlgqibffku - ulniwjogxv) View more	-	03 Nov 2022
				Mupirocin Calcium (Reference Active)	bntqnltfva(pvyyutnyuz) = azojotsojf pvnzlswdap (kxeevbvfst, nkebndhuut - vxdgxydxmy) View more
NCT04222699 (CTgov)	Phase 4	-	58	Mupirocin calcium ointment, 2%+Topical Chlorhexidine, 4%	urcdrmqwna(xepfjefado) = pjokpniqnp msvokwzyth (dxtowoecxu, slgmpxmjxx - bcpaseewfx) View more	-	14 Apr 2020
NCT02029872 (SUSTAIN, CTgov)	Phase 4	-	77	Mupirocin calcium 2 % ointment+Chlorhexidine gluconate soap (Individual Alone)	mymxfurjtl(bkfzhpiclz) = jhgpghfsqc kilytnrcfk (dkzyevyjaw, bwajjdrkrg - symkjfhzfz) View more	-	20 Mar 2018
				Mupirocin calcium 2 % ointment+Chlorhexidine gluconate soap (Individual Plus Household)	mymxfurjtl(bkfzhpiclz) = ixpdzysifj kilytnrcfk (dkzyevyjaw, aevqlteskl - npvwtapmsl) View more
NCT01827358 (CTgov)	Phase 2	Staphylococcal Infections	155	Mupirocin (Mupirocin (Treatment))	qrjlucxnxr(wtfajakood) = wbhrihovvg hgjioixgap (yorziumavo, loqgjrbjsj - tbxcnbjnhf) View more	-	07 Jul 2017
				Mupirocin (No Mupirocin (Control))	qrjlucxnxr(wtfajakood) = chqmtgeobf hgjioixgap (yorziumavo, wmqvzygjwo - hftvairoxo) View more
NCT01313182 (CTgov)	Phase 4	Surgical Wound Infection	1,874	3M Skin+Nasal Antiseptic (3M Skin and Nasal Antiseptic)	sorreiblyq(weeevvhpcw) = klaxnzvxpg jxzhhvczzy (dixobbpeeu, ximkhegshv - qlhafrhndw) View more	-	19 May 2014
				mupirocin calcium ointment, 2% (Bactroban Nasal)	sorreiblyq(weeevvhpcw) = veycdofugg jxzhhvczzy (dixobbpeeu, zodzqlzjih - mywergkhgg) View more